Centre for Obesity Research and Epidemiology (CORE), Faculty of Health and Social Care, Robert Gordon University, Aberdeen, Scotland, UK.
Diabetes Metab Syndr Obes. 2013 Oct 11;6:393-401. doi: 10.2147/DMSO.S51151. eCollection 2013.
Very low-calorie diets (VLCDs) are an effective means by which to induce clinically significant weight loss. However, their acceptance by health care practitioners and the public is generally lower than that for other nonsurgical weight loss methods. Whilst there is currently little evidence to suggest they have any detrimental effect on hepatic and renal health, data assessing these factors remain limited. We carried out a systematic review of the literature on randomized controlled trials that had a VLCD component and that reported outcomes for hepatic and renal health, published between January 1980 and December 2012. Cochrane criteria were followed, and eight out of 196 potential articles met the inclusion criteria. A total of 548 participants were recruited across the eight studies. All eight studies reported significant weight loss following the VLCD. Changes in hepatic and renal outcomes were variable but generally led to either no change or improvements in either of these. Due to the heterogeneity in the quality and methodology of the studies included, the effect of VLCDs on hepatic and renal outcomes remains unclear at this stage. Further standardized research is therefore required to fully assess the impact of VLCDs on these outcome measures, to better guide clinical practice.
极低热量饮食(VLCD)是一种有效诱导临床显著体重减轻的方法。然而,它们在医疗保健从业者和公众中的接受程度通常低于其他非手术减肥方法。虽然目前几乎没有证据表明它们对肝脏和肾脏健康有任何不良影响,但评估这些因素的数据仍然有限。我们对 1980 年 1 月至 2012 年 12 月间发表的关于 VLCD 成分并报告肝脏和肾脏健康结果的随机对照试验进行了系统综述。我们遵循了 Cochrane 标准,在 196 篇潜在文章中有 8 篇符合纳入标准。在这 8 项研究中共有 548 名参与者被招募。所有 8 项研究均报告 VLCD 后体重显著减轻。肝肾功能结果的变化各不相同,但通常要么没有变化,要么有所改善。由于纳入研究的质量和方法学存在异质性,VLCD 对肝肾功能结果的影响在现阶段仍不清楚。因此,需要进一步进行标准化研究,以全面评估 VLCD 对这些结果指标的影响,从而更好地指导临床实践。